Last reviewed · How we verify
NCT05366036
A Study for Tecfidera (Dimethyl Fumarate) Capsules in Korean Participants With Relapsing-Remitting Multiple Sclerosis
trial testing No Intervention in Multiple Sclerosis, Relapsing-remitting in 172 participants. Completed in 14 January 2022.
14 January 2022
Quick facts
| Lead sponsor | Eisai Korea Inc. |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 172 |
| Start date | 14 June 2017 |
| Primary completion | 14 January 2022 |
| Estimated completion | 14 January 2022 |
| Sites | 20 locations across South Korea |
Drugs / interventions tested
- No Intervention
Conditions studied
- Multiple Sclerosis, Relapsing-remitting — all drugs for Multiple Sclerosis, Relapsing-remitting →
Sponsor
Eisai Korea Inc. — full company profile →
Who can join
Adults 18 to 55, any sex, with Multiple Sclerosis, Relapsing-remitting. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary purpose of this study is to evaluate the overall safety and efficacy of Tecfidera (Dimethyl Fumarate) as an oral treatment for Korean participants with relapsing-remitting multiple sclerosis (MS) under routine clinical practice.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05366036
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of No Intervention
Trials testing the same drug.
- NCT07353099 — A Study in Children and, Adults With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Treated With Adzynma · not yet recruiting
- NCT07429942 — A Study to Learn More About the Treatment of People With Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Who Recei · not yet recruiting
- NCT07521917 — Child Abuse and Neglect Awareness Training in Nursing Students · NA · not yet recruiting
- NCT07319832 — A Study of Teduglutide in Chinese Children and Teenagers With Short Bowel Syndrome · recruiting
- NCT07425574 — A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults · recruiting
Other Eisai Korea Inc. trials
Trials by the same sponsor.
- NCT06964113 — A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine · Phase 4 · recruiting
- NCT06810960 — A Postmarketing Study of Lecanemab in South Korean Participants With Alzheimer's Disease · recruiting
- NCT06625242 — A Study of Filgotinib in Korean Participants With Rheumatoid Arthritis · Phase 4 · active not recruiting
- NCT06246123 — A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants · recruiting
- NCT05533814 — A Study to Evaluate the Efficacy and Safety of Perampanel Monotherapy in Untreated Participants With Focal Onset Seizure · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05366036 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Eisai Korea Inc.
- Last refreshed: 9 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05366036.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing